TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic

EbsArgent targets urinary tract infections, with early indications of efficacy against many species of multidrug-resistant bacteria STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Thioredoxin Systems AB (TXN Systems), a pharmaceutical company developing a first-in-class antibiotic for...